Neurology

Artificial Intelligence in Diagnostics Market Size worth US$ 5.44 billion by 2030 – Exclusive Report by The Research Insights

CHICAGO, May 21, 2025 /PRNewswire/ -- The global Artificial Intelligence in Diagnostics Market Size is projected to be valued at USD 1.97…

7 months ago

Neurophet Participates ASNR 2025: Showcasing Clinical Utility of ‘Neurophet AQUA AD’

Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA ADCompany accelerates…

7 months ago

Neurogen Biomarking Announces Partnership with Aranscia

Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and…

7 months ago

Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study

Data from 250-patient, 31-center, randomized controlled trial presented at European Stroke Organisation Conference Three highest enrolling sites reported 96% delivery…

7 months ago

Rapport Therapeutics to Host 2025 Investor and Analyst Day

BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated…

7 months ago

ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows

HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that…

7 months ago

Natus announces entry into Point-of-Care EEG with launch of BrainWatch

MIDDLETON, Wis., May 20, 2025 /PRNewswire/ -- Natus Medical Incorporated has announced the official launch of BrainWatch™, the highly anticipated…

7 months ago

McFarland Clinic Taps Nabla to Support Clinicians and Streamline Documentation in Epic

Following a successful pilot, Nabla is now used across 12 specialties at McFarland Clinic to help clinicians spend less time on…

7 months ago

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria…

7 months ago